First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia
University of Cologne · Düsseldorf University Hospital · +33 more institutions
Abstract
Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking. Download a PDF of the Research Summary. In a phase 3, open-label trial, we randomly assigned, in a 1:1:1:1 ratio, fit patients with CLL who did not have TP53 aberrations to receive six cycles of chemoimmunotherapy (fludarabine–cyclophosphamide–rituximab or bendamustine–rituximab) or 12 cycles of venetoclax–rituximab, venetoclax–obinutuzumab, or venetoclax–obinutuzumab–ibrutinib. Ibrutinib was discontinued after two consecutive measurements of undetectable minimal residual disease or could be…
Citation impact
- FWCI
- 75.58
- Percentile
- 100%
- References
- 30
Authors
50- BEBarbara EichhorstCorresponding
University of Cologne, Düsseldorf University Hospital, Integrated Oncology (United States), University Hospital Cologne, Heinrich Heine University Düsseldorf, Ludwig-Maximilians-Universität München
- CUCarsten Utoft Niemann
Copenhagen University Hospital, Rigshospitalet, Düsseldorf University Hospital, University Hospital Cologne, Heinrich Heine University Düsseldorf, Ludwig-Maximilians-Universität München
- APArnon P. Kater
University Medical Center, Düsseldorf University Hospital, University Hospital Cologne, Heinrich Heine University Düsseldorf, Ludwig-Maximilians-Universität München, University of Amsterdam
- MFMoritz Fürstenau
University of Cologne, Düsseldorf University Hospital, Integrated Oncology (United States), University Hospital Cologne, Heinrich Heine University Düsseldorf, Ludwig-Maximilians-Universität München
- JVJulia von Tresckow
Düsseldorf University Hospital, University Hospital Cologne, Heinrich Heine University Düsseldorf, University of Duisburg-Essen, Ludwig-Maximilians-Universität München
Topics & keywords
- Venetoclax
- Obinutuzumab
- Chemoimmunotherapy
- Ibrutinib
- Rituximab
- Medicine
- Chronic lymphocytic leukemia
- Bendamustine
- Good health and well-being